Brief: Aquestive Therapeutics Inc Reports Positive Topline Data From Temperature / pH Study Of Anaphylm™ (Epinephrine) Sublingual Film
25/06/2024 13:37
June 25 (Reuters) - Aquestive Therapeutics Inc AQST.O :
* AQUESTIVE THERAPEUTICS INC: REPORTS POSITIVE TOPLINE DATA
FROM
TEMPERATURE / PH STUDY OF ANAPHYLM™ (EPINEPHRINE) SUBLINGUAL
FILM
* AQUESTIVE THERAPEUTICS INC: ON TRACK TO COMPLETE ANAPHYLM
SUPPORTIVE CLINICAL STUDIES, EXPECTS TO REQUEST PRE-NDA MEETING
WITH FDA IN Q3
* AQUESTIVE THERAPEUTICS: SEES FILING NDA SHORTLY AFTER
COMPLETION
OF PEDIATRIC STUDY OF ANAPHYLM
Source text for Eikon: ID:nGNX54XGyv
Further company coverage: AQST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aquestive Therapeutics
See all newsBrief: Aquestive Therapeutics Inc - Enters Five-Year Term Loan Facility Of Up To $150 Million On May 12, 2026 - SEC Filing
Aquestive Therapeutics Q1 revenue jumps on higher license and royalty income
Brief: Aquestive Therapeutics Announces Completion Of Type A Meeting With FDA For Anaphylm™ (Dibutepinephrine) Sublingual Film
Aquestive misses Q4 revenue estimates, EBITDA loss widens
Brief: Aquestive Therapeutics, Inc. Q4 Net Income USD -31.86 Million